Multiple Myeloma in Relapse Withdrawn Phase 2 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01329289SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple MyelomaTreatment